Paul-Ehrlich-Institut, Langen, Germany.
Paul-Ehrlich-Institut, Langen, Germany.
J Clin Virol. 2019 Oct;119:60-67. doi: 10.1016/j.jcv.2019.05.006. Epub 2019 May 14.
Globally, hepatitis E virus (HEV) is a major cause of acute viral hepatitis. Epidemiology and clinical presentation of hepatitis E vary greatly by location and are affected by the HEV genotype. Nucleic acid amplification technique (NAT)-based assays are important for the detection of acute HEV infection as well for monitoring chronic cases of hepatitis E.
The aim of the study was to evaluate a panel of samples containing different genotypes of HEV for use in nucleic NAT-based assays.
The panel of samples comprises eleven different members including HEV genotype 1a (2 strains), 1e, 2a, 3b, 3c, 3e, 3f, 4c, 4g as well as a human isolate related to rabbit HEV. Each laboratory assayed the panel members directly against the 1 World Health Organization (WHO) International Standard (IS) for HEV RNA (6329/10) which is based upon a genotype 3 a strain.
The samples for evaluation were distributed to 24 laboratories from 14 different countries and assayed on three separate days. Of these, 23 participating laboratories returned a total of 32 sets of data; 17 from quantitative assays and 15 from qualitative assays. The assays used consisted of a mixture of in-house developed and commercially available assays. The results showed that all samples were detected consistently by the majority of participants, although in some cases, some samples were detected less efficiently.
Based on the results of the collaborative study the panel (code number 8578/13) was established as the "1st International Reference Panel (IRP) for all HEV genotypes for NAT-based assays" by the WHO Expert Committee on Biological Standardization. This IRP will be important for assay validation and ensuring adequate detection of different genotypes and clinically important sub-genotypes of HEV.
在全球范围内,戊型肝炎病毒(HEV)是急性病毒性肝炎的主要病因。戊型肝炎的流行病学和临床表现因地理位置而异,受 HEV 基因型的影响。基于核酸扩增技术(NAT)的检测方法对于急性 HEV 感染的检测以及慢性 HEV 病例的监测都非常重要。
本研究旨在评估一组包含不同 HEV 基因型的样本,用于基于核酸的 NAT 检测。
该样本组由 11 个不同成员组成,包括 HEV 基因型 1a(2 株)、1e、2a、3b、3c、3e、3f、4c、4g 以及一株与兔 HEV 相关的人源分离株。每个实验室直接对包含在 1 个世卫组织(WHO)国际标准(IS)中的 11 个样本成员进行检测(6329/10),该标准基于一株 3a 基因型的病毒。
评估样本被分发给来自 14 个不同国家的 24 个实验室,并在 3 个不同的日期进行检测。其中,23 个参与实验室共返回了 32 组数据;17 组定量数据和 15 组定性数据。使用的检测方法包括内部开发和商业化的检测方法的组合。结果表明,虽然在某些情况下,某些样本的检测效率较低,但大多数参与者一致检测到了所有样本。
根据协作研究的结果,该小组(编号 8578/13)被世卫组织生物标准化专家委员会确认为用于基于 NAT 的检测的“所有 HEV 基因型的第 1 个国际参考小组(IRP)”。该 IRP 将对检测方法的验证和确保对不同基因型和临床上重要的亚基因型的 HEV 的充分检测非常重要。